Company Profile
ProQR Therapeutics Stock Price, News & Catalysts
- Ticker:
- PRQR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Netherlands and listed in the U
Stock performance
1.93 USD (+0.52%)
Close
Last updated: August 17, 2026
155M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, PRQR closed up 0.52% at $1.93. No new same-company headline was identified in the current news window.
Company overview
RNA Editing Company
ProQR Therapeutics develops RNA-editing medicines using its Axiomer platform.
Axiomer Technology
Axiomer recruits endogenous ADAR enzymes to make precise single-base changes in RNA without permanently altering DNA.
AX-0810
AX-0810 targets NTCP and is being developed initially for biliary atresia, with early clinical work measuring target engagement in healthy volunteers.
Pipeline Expansion
Additional programs include AX-0811 and IDUA-targeting AX-0422, supported by internal and partnered discovery capabilities.
Future catalysts
- Full Phase 1 dataset for AX-0810 at a medical or scientific conference later in 2026.
- Initial Phase 1 data for AX-0811 by the end of 2026.
- Initiation and initial data from the biliary-atresia investigator study in the first half of 2027.
- Initial patient data for AX-0422 in MPS I Hurler syndrome in the first half of 2027.
- Advancement of AX-2911 into clinical development in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ProQR Therapeutics (PRQR)?
ProQR Therapeutics (PRQR) most recently closed at 1.93 USD, a +0.52% move versus the previous session.
What is the market cap of ProQR Therapeutics (PRQR)?
ProQR Therapeutics currently has a market capitalization of 155M USD on BioPharmSignal.
What does ProQR Therapeutics do?
RNA Editing Company ProQR Therapeutics develops RNA-editing medicines using its Axiomer platform. Axiomer Technology Axiomer recruits endogenous ADAR enzymes to make precise single-base changes in RNA without permanently altering DNA. AX-0810 AX-0810 targets NTCP and is being developed initially for biliary atresia, with early clinical work measuring target...
On which exchange is PRQR stock listed?
ProQR Therapeutics (PRQR) is associated with NASDAQ, Netherlands and listed in the U, Biopharma.
What is AX-0810?
Full Phase 1 dataset for AX-0810 at a medical or scientific conference later in 2026.
Which conditions is ProQR Therapeutics targeting with AX-0810?
Full Phase 1 dataset for AX-0810 at a medical or scientific conference later in 2026.
How does ProQR Therapeutics describe recent progress with AX-0810?
Full Phase 1 dataset for AX-0810 at a medical or scientific conference later in 2026.
What is AX-0811?
Pipeline Expansion Additional programs include AX-0811 and IDUA-targeting AX-0422, supported by internal and partnered discovery capabilities.